Intellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA - Free Report) in a research report released on Thursday morning,RTT News reports. The brokerage currently has a $7.00 target price on the stock, down from their prior target price of $10.00.

NTLA has been the topic of a number of other reports. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Intellia Therapeutics in a report on Thursday. Barclays lowered their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. The Goldman Sachs Group reissued a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Wall Street Zen upgraded Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Finally, Chardan Capital reaffirmed a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $36.75.

Intellia Therapeutics Stock Up 4.2%

NTLA stock traded up $0.29 during trading on Thursday, reaching $7.16. The company's stock had a trading volume of 7,943,729 shares, compared to its average volume of 3,695,733. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18. The company's fifty day moving average is $7.93 and its 200-day moving average is $10.23. The company has a market capitalization of $741.65 million, a P/E ratio of -1.32 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same period last year, the company earned ($1.12) EPS. The firm's revenue for the quarter was down 42.6% on a year-over-year basis. Analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently made changes to their positions in NTLA. Barclays PLC increased its position in Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after purchasing an additional 44,022 shares during the period. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after buying an additional 280,946 shares during the period. SG Americas Securities LLC increased its holdings in Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock valued at $523,000 after buying an additional 20,694 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth $4,793,000. Finally, Baker BROS. Advisors LP bought a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $7,510,000. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.